By David Tuller, DrPH In an eagerly awaited draft report, an Australian advisory committee on ME/CFS has called for the development of up-to-date domestic clinical guidelines and an increase in biomedical research into the pathophysiology of the illness. The draft report, which could have a major impact on health policy going forward, also highlights the …
Trial By Error: Australian Draft Report Seeks Comments Read More »
By David Tuller, DrPH I haven’t had time to cover the new and wildly over-hyped study about prolonged fatigue–and purportedly about “chronic fatigue syndrome”–that was published this week in the journal Psychoneuroendocrinology. Thanks no doubt to the involvement of the Science Media Centre, this mildly interesting piece of research has received widespread media attention.
By David Tuller, DrPH I spent the last week of November in Oslo. The Norwegian ME Association invited me to give a couple of talks and have some meetings with public health officials. The city was charming, even if dark and overcast at this time of year. Not surprisingly, the same tussle taking place over …
By David Tuller, DrPH Yet another interesting development has taken place at Cochrane, and this new development again suggests that things there might be moving in the right direction. On Friday, the organization withdrew a protocol for what is called an individual patient data (or IPD) review of exercise therapy for the illness it has …
Trial By Error: And Cochrane Makes Another Move… Read More »
By David Tuller, DrPH Earlier today, I sent the following e-mail to Dr Fiona Godlee, editorial director of BMJ. I cc’d Carol Monaghan MP, Darren Jones MP, and Nicky Morgan MP. I also cc’d Teresa Allen of the Health Research Authority. ********** Dear Dr. Godlee, As you know, I have spent some time criticizing a …
Trial By Error: How BMJ Enabled Bristol’s Ethics Exemptions Read More »
By David Tuller, DrPH In what can only be characterized as a welcome surprise, Cochrane has rejected the revision of a 2014 review of exercise treatments for chronic fatigue syndrome, stating that the work does not meet the organization’s quality standards. Cochrane revealed the decision late Friday in a statement appended to the review, which …
